

REGISTERED NUMBER: 13249305 (England and Wales)

Financial Statements for the Period 8 March 2021 to 31 March 2022

for

Mediform London Limited

**Contents of the Financial Statements
for the Period 8 March 2021 to 31 March 2022**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

Mediform London Limited
Company Information
for the Period 8 March 2021 to 31 March 2022

DIRECTOR:	Dr R Hughes
REGISTERED OFFICE:	Unit 17 The Matchworks 140 Speke Road Liverpool Merseyside L19 2RF
REGISTERED NUMBER:	13249305 (England and Wales)
ACCOUNTANTS:	Cobham Murphy 116 Duke Street Liverpool Merseyside L1 5JW

Mediform London Limited (Registered number: 13249305)

**Balance Sheet
31 March 2022**

	Notes	£	£
FIXED ASSETS			
Tangible assets	4		96
CURRENT ASSETS			
Stocks		45,000	
Debtors	5	18,472	
Cash at bank		<u>2,125</u>	
		65,597	
CREDITORS			
Amounts falling due within one year	6	<u>62,418</u>	
NET CURRENT ASSETS			<u>3,179</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>3,275</u>
CAPITAL AND RESERVES			
Called up share capital			100
Retained earnings			<u>3,175</u>
			<u>3,275</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2022.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2022 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 8 March 2023 and were signed by:

Dr R Hughes - Director

The notes form part of these financial statements

**Notes to the Financial Statements
for the Period 8 March 2021 to 31 March 2022**

1. STATUTORY INFORMATION

Mediform London Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The director has considered the consequences of COVID-19 and other events and conditions, and they have determined that they do not create a material uncertainty that casts significant doubt upon the entity's ability to continue as a going concern.

Significant judgements and estimates

There are no judgements (apart from those involving estimates) that have had a significant effect on amounts recognised in the financial statements.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is measured at the fair value of the manufacture of medical and dental instruments and supplies received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Revenue is recognised when it is probable that future economic benefits will flow to the entity.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 15% on reducing balance

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments

Directors loans and intercompany loans (being repayable on demand), trade debtors and trade creditors are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Notes to the Financial Statements - continued
for the Period 8 March 2021 to 31 March 2022

2. **ACCOUNTING POLICIES - continued**

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the period was NIL.

4. **TANGIBLE FIXED ASSETS**

	Plant and machinery etc £
COST	
Additions	104
At 31 March 2022	<u>104</u>
DEPRECIATION	
Charge for period	8
At 31 March 2022	<u>8</u>
NET BOOK VALUE	
At 31 March 2022	<u>96</u>

5. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	£
Amounts owed by associates	9,590
Other debtors	8,882
	<u>18,472</u>

6. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	£
Trade creditors	15,853
Amounts owed to associates	42,000
Taxation and social security	516
Other creditors	4,049
	<u>62,418</u>

7. **DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES**

Included in debtors is £407 due from the director which is repayable on demand. Interest is charged at a rate of 2%.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.